Study of VIP943 in Subjects with Advanced CD123+ Hematologic Malignancies
NCT06034275
DESCRIPTION OF STUDY
This is a Phase 1 dose-escalation study. The purpose of the study is to determine the maximum tolerated dose, if possible, or minimum optimal biologic dose, and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies.
ELIGIBILITY
- Age: 18+
- Sex: Both
- Status: Recruiting